ClinicalTrials.gg
RecruitingNCT06155916Updated Mar 14, 2025

Sleep and Neuropathic Pain - Intervention Study on Pregabalin

An interventional study of Pregabalin in Neuropathic Pain, Insomnia and Sleep Disorder, sponsored by Helsinki University Central Hospital. Recruiting at 2 sites in Finland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by Helsinki University Central Hospital · Not applicable, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Nov 2022, registered May 2023).
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.

Planned enrollment
43rd of 50
40 · median 109
Started
2022
with 5 others
No phase
10 of 50
2 open now
Registered
46th of 50
by date

Among the 50 studies testing pregabalin in Neuralgia, this one is the 43rd largest by planned enrollment, is one of 6 that started in 2022, is one of 10 with no phase, and was the 46th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing pregabalin in Neuralgia, or all of them as a file.
02

Study summary

The goal of this clinical study is to study sleep and its microstructure in neuropathic pain patients who have or who do not have a clinically significant sleep disturbance, before and during (after 1-month stabile dosage) pregabalin treatment. To find out whether reduced pain by pregabalin associates with improved sleep quality; to study, using resting state fMRI, brain network connectivity and the volume of the choroid plexus before and during pregabalin treatment (after dosage stable for one month) at baseline and during stabile treatment with pregabalin, and to compare the usability and reliability of sleep-related information collected with sleep diaries, actigraphy, iButtons, and ambulatory polysomnography in peripheral painful neuropathy patients. The main questions it aims to answer are:

  • Is pregabalin more efficacious in neuropathic pain patients who suffer from insomnia compared to those with no clinically meaningful sleep disturbance?
  • Does sleep disturbance due to pain associate with brain network connectivity and may these changes be reversed by pregabalin treatment? Participants will
  • Fulfill e-questionnaires and keep sleep diary before and after 1month stabile pregabalin intervention
  • Before and after 1-month stabile pregabalin medication: 1-week Actiwatch monitoring, iButton (1 day and night), ambulatory polysomnography (1 night), brain fMRI.

Researchers will compare patients with high ISI score patients to see if they benefit more from pregabalin treatment than those with low ISI score.

Read the detailed description

This is a clinical study to analyze sleep and pain and their response to pregabalin in 40 patients aged 18 to 75 years with chronic (duration>3 months) moderate to severe pain (NRS ≥ 4/10) due to peripheral neuropathy. The investigators divide patients to two groups according to scores in ISI: the ones with clinically significant insomnia with score 15 or more (ISI High) and the ones without marked insomnia with score 14 or lower (ISI Low). Sleep will be assessed by a sleep diary, iButton, polysomnography and 1-week Actiwatch monitoring before and after 1-month stabile pregabalin dosage. Additionally, at these time points, several questionnaires regarding pain, sleep, mood, and quality of life and functional brain MRI will be performed. At pregabalin administration, the dose is added three to four day intervals, if tolerated by the patient. After a maximum tolerated dose has been stable for 1 month, the sleep studies, questionnaires, and brain fMRI are repeated. The study duration is about 3 months.

03

Conditions studied

  • Neuropathic Pain
  • Insomnia
  • Sleep Disorder

Keywords

  • polysomnography
  • actigraphy
  • fMRI
  • pregabalin
  • neuropathic pain
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic (duration > 3 months) painful peripheral neuropathy
  • Pain moderate to severe (NRS ≥ 4/10) during the past week

Exclusion criteria

Exclusion Criteria:

  • psychotic depression, bipolar disorder
  • for performing brain fMRI (metal in the body etc)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    High ISI

    Patients that have clinically significant insomnia according to ISI questionnaire (score 15 or more) at baseline.

    Drug: Pregabalin

  • Experimental
    Low ISI

    Patients with no clinically significant insomnia according to ISI questionnaire (score 14 or less) at baseline.

    Drug: Pregabalin

Interventions

  • Pregabalin administration and titration to the highest dosage that the patient tolerates. The patient continues with the highest dose for one month and the pre-intervention studies are repeated.

    Also known as: Pregabalin for high insomnia patients with painful neuropathy, Pregabalin for low insomnia patients with painful neuropathy

06

What researchers measure

Primary outcomes

  1. Pregabalin response to pain

    Pain intensity and interference assessed by numeric rating scale

    Time frame: Change from baseline pain intensity and interference immediately after the intervention

  2. Pregabalin effect on sleep stages

    1-night Ambulatory Polysomnography (NREM stage III)

    Time frame: Change from baseline immediately after the intervention

  3. Sleep disturbance associations to brain network connectivity

    Brain fMRI for brain network connectivity

    Time frame: Change from baseline immediately after the intervention

  4. Sleep disturbance associations to choroid plexus volume in brain fMRI

    Brain fMRI for choroid plexus volume measures

    Time frame: Change from baseline immediately after the intervention

  5. Pregabalin effect on circadian rhythms

    1-week actigraphy

    Time frame: Change from baseline immediately after the intervention

  6. Pregabalin effect on body temperature during sleep

    1-night body temperature measurement by iButton

    Time frame: Change from baseline immediately after the intervention

07

Study locations

2 of 2 sites recruiting
  • Helsinki University Central Hospital
    Helsinki, HUS 00029, Finland
    Recruiting
    • Hanna T Harno, MD, PhD · Contacthanna.harno@hus.fi · +358503427375
    • Eija Kalso, MD, PhD · Principal investigator
    • Miguel Munoz, MD, PhD · Sub investigator
    • Yevhen Hlushchuk, MD, PhD · Sub investigator
  • Helsinki University Hospital, Department of Neurology
    Helsinki, Uusimaa 00029, Finland
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2025, 37 months after the start.

Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 37 months is above that.

Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2023
First posted
Dec 5, 2023
StartActual
Nov 22, 2022
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2026
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06155916
Responsible party
Hanna Harno (Director, Helsinki University Central Hospital) — Principal investigator
First posted
Dec 5, 2023
Start date
Nov 22, 2022
Primary completion
Dec 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 14, 2025

Study contacts

Hanna Harno, PhD
Contact
hanna.harno@hus.fi
+358503427375
Eija Kalso, PhD
Contact
eija.kalso@helsinki.fi
+358504270609
Hanna Harno, PhD
study chair · Helsinki University Hospital, Department of Neurology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion